Merck ADC Drug Cuts Death Risk 32% in Advanced Endometrial Cancer
Merck’s antibody-drug conjugate reduced the risk of death by 32% among patients with advanced endometrial cancer.
Merck’s antibody-drug conjugate reduced the risk of death by 32% among patients with advanced endometrial cancer.